LAURUS LABS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 450 INR | +1.41% |
|
+4.64% | +4.60% |
| Apr. 25 | Transcript : Laurus Labs Limited, Q4 2024 Earnings Call, Apr 25, 2024 | |
| Apr. 25 | Laurus Labs' Consolidated Profit Falls in Fiscal Q4 | MT |
| Sales 2024 | 50.41B 604M | Sales 2025 * | 58.96B 706M | Capitalization | 243B 2.91B |
|---|---|---|---|---|---|
| Net income 2024 | 1.61B 19.24M | Net income 2025 * | 4.43B 53.06M | EV / Sales 2024 | 4.2 x |
| Net Debt 2024 * | 18.41B 220M | Net Debt 2025 * | 22.35B 268M | EV / Sales 2025 * | 4.49 x |
| P/E ratio 2024 |
132
x | P/E ratio 2025 * |
56.2
x | Employees | 5,753 |
| Yield 2024 * |
0.29% | Yield 2025 * |
0.33% | Free-Float | 65.41% |
More Fundamentals
* Assessed data
More news
Latest transcript on Laurus Labs Limited
More recommendations
| 1 day | +1.41% | ||
| 1 week | +4.64% | ||
| Current month | +14.69% | ||
| 1 month | +14.69% | ||
| 3 months | +20.26% | ||
| 6 months | +26.12% | ||
| Current year | +4.60% |
1 week
414.60
455.30
1 month
393.10471.00
Current year
360.85471.00
1 year
299.30471.00
3 years
278.85723.75
5 years
59.00723.75
10 years
59.00723.75
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 63 | 05-09-18 | |
| Director of Finance/CFO | - | 06-11-29 | |
S. Srinivasa Rao
COO | Chief Operating Officer | - | 08-04-01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 63 | 05-09-18 | |
| Chairman | 83 | 17-05-23 | |
| Director/Board Member | 68 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.21% | 6 M€ | +6.07% | - | |
| 0.02% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 450 | +1.41% | 2,479,566 |
| 24-04-29 | 443.8 | +1.56% | 2,183,161 |
| 24-04-26 | 437 | +2.59% | 8,553,636 |
| 24-04-25 | 425.9 | -1.96% | 3,421,872 |
| 24-04-24 | 434.4 | +0.30% | 730,062 |
Delayed Quote NSE India S.E., April 30, 2024 at 07:42 am EDT
More quotes
Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The Company offers integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. The Company operates through three segments: Laurus Generics, Laurus Synthesis, and Laurus Bio. The Laurus Generics segment comprises API and FDF-Development, manufacture and sale of APIs and advanced intermediates and oral solid formulations/FDF. Laurus Synthesis segment comprises key starting materials (KSM), intermediates and APIs for new chemical entities (NCEs). Laurus Bio segment comprises recombinant products, animal origin free products for safer and viral free bio manufacturing. The Company operates through two geographical segments: Revenue from customers within India-Domestic, and Revenue from customers outside India-Exports. The Company sell its APIs in 56 countries.
Sector
Pharmaceuticals
Calendar
2024-07-11
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
450
INR
Average target price
383.4
INR
Spread / Average Target
-14.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.60% | 2.91B | |
| +34.00% | 704B | |
| +29.29% | 577B | |
| -7.75% | 348B | |
| +18.53% | 327B | |
| +4.95% | 288B | |
| +13.79% | 234B | |
| +4.93% | 198B | |
| -9.78% | 194B | |
| -4.89% | 147B |
- Stock Market
- Equities
- LAURUSLABS Stock
